Cardiovascular Outcomes Trial
Abbreviation: CVOT
Definition
A large clinical study designed to determine whether a diabetes or metabolic drug reduces or increases the risk of major cardiovascular events such as heart attack, stroke, or cardiovascular death.
Cardiovascular Outcomes Trial
A cardiovascular outcomes trial (CVOT) is a large-scale, randomized, controlled clinical study specifically designed to evaluate the effect of a therapeutic agent on major adverse cardiovascular events (MACE). The typical primary endpoint of a CVOT is a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, sometimes referred to as three-point MACE. Some trials expand this composite to include hospitalization for unstable angina (four-point MACE). CVOTs became a regulatory requirement for new diabetes therapies following a 2008 FDA guidance document that mandated demonstration of cardiovascular safety for all novel glucose-lowering agents, prompted by concerns raised by the thiazolidinedione rosiglitazone.
CVOTs are typically event-driven trials, meaning they continue until a prespecified number of cardiovascular events has been adjudicated, regardless of the duration of follow-up. This design requires enrollment of thousands of participants, often those at high cardiovascular risk, and may span several years. The statistical goal is to demonstrate non-inferiority of the investigational drug versus placebo (added to standard of care) with respect to MACE, with the upper bound of the 95% confidence interval for the hazard ratio falling below 1.3. Several incretin-based therapies have gone beyond demonstrating safety and have shown statistically significant cardiovascular benefit in CVOTs, including liraglutide (LEADER trial) and semaglutide (SELECT trial).
Clinical Relevance to Retatrutide
A dedicated cardiovascular outcomes trial for retatrutide is anticipated as part of its broader clinical development program. Given the substantial weight loss and metabolic improvements observed in earlier-phase studies, there is scientific interest in whether retatrutide’s triple receptor agonism may confer cardiovascular benefits beyond those seen with GLP-1 receptor agonists alone. The glucagon receptor agonism component may contribute to favorable effects on lipid metabolism and hepatic fat reduction, while the magnitude of weight loss itself is expected to improve multiple cardiometabolic risk factors. Results from a CVOT will be essential for establishing the full clinical value of retatrutide in patients with type 2 diabetes and obesity who are at elevated cardiovascular risk.